Construction of the tailor-made medicine for prostate cancer with bone metastasis using bone turnover metabolites

伴有骨转移的前列腺癌患者血清MMP-2水平与肿瘤分级及骨转移程度相关。我们测定了唑来膦酸（ZA）对激素敏感的前列腺癌合并骨转移患者血清PSA和骨转换标志物的加性作用，这些患者接受了联合雄激素阻断（CAB）治疗。与单用CAB治疗相比，在CAB治疗中加入ZA可显示PSA和ALP反应，提示ZA在转移性PCa患者的治疗中具有潜在的抗肿瘤作用。此外，为了明确替代非甾体抗雄激素治疗（AA）后PSA降低>50%的临床预测因素，并开发一种nomogram来预测初始CAB后复发的晚期PCa患者在AA后PSA降低>50%。受试者工作特征曲线表明，该模型预测概率的准确率为72.5%。

Serum MMP-2 level correlated with tumor grade and the extent of bone metastases in prostate cancer (PCa) with bone metastases. We determined that the additive effect of zoledronic acid (ZA) on serum PSA and bone turnover markers changes for hormone-sensitive PCa patients with bone metastasis treated by combined androgen blockade (CAB). The addition of ZA to CAB therapy showed PSA and ALP response compared with CAB therapy only, suggesting a potential antitumor effect of ZA in the management of metastatic PCa patients.Furthermore, to clarify clinical predictors for a PSA decrease >50% in response to alternative non-steroidal antiandrogen therapy (AA) and to develop a nomogram to predict the PSA decrease >50% in response to AA in patients with advanced PCa that relapsed after initial CAB. The receiver operating characteristic curve showed that the accuracy of the predicted probability was 72.5% for the model.